Our website uses cookies to distinguish you from other users of our website to provide you with the most relevant experience by remembering your preferences and repeat visits. By clicking on ‘Accept’ you consent to our cookie policy. However, you may visit ‘Cookie Settings’ to provide a controlled consent.

Accept

News

Archive

NorthSea Therapeutics to present ICONA Phase 2b data as an oral late-breaker session at the 2023 AASLD Liver Meeting Zeotap Data offers digital media buyers precision and reach against their core demographic audiences. Validated with persistent, factual data, accuracy far exceeds big tech DSPs Ventyx Biosciences announces results from the Phase 2 trial of VTX958 in patients with moderate to severe plaque psoriasis and provides corporate update NorthSea Therapeutics receives FDA Rare Pediatric Disease Designation for SEFA-6179 for the treatment of Intestinal Failure-Associated Liver Disease Glydways announces $56 Million Series B Round with New Science Ventures, ACS Group, Khosla Ventures and Gates Frontier Paragraf named Business of the Year in Cambridge glory parade
Back To News
ProterixBio
September 28, 2017

ProterixBio

Focused on the development of molecular assessments to improve the management of chronic diseases, with an initial focus on COPD.

Cookie Policy Privacy Policy